Tenofovir Alafenamide (TAF) in Children and Adolescents With Chronic Hepatitis B Virus Infection
Summary
- Eligibility
- for people ages 2-17 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Philip Rosenthal
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Gilead Sciences
- ID
- NCT02932150
- Phase
- Phase 2
- Study Type
- Interventional
- Last Updated